Company · CIK 0001643848 · SIC 2834 — Pharmaceutical Preparations
Patheon N.V. · PTHN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 29, 2017 UForm 4 → | Aug 31, 6:30 pm EDT | Michel LagardePresident | 245,939 | — | — | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 31, 6:28 pm EDT | Dean Frederick WilsonChief Accounting Officer | 126,518 | — | — | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:28 pm EDT | Lukas UtigerPresident, Drug Substance Svcs | 577,946 | $35.00 | $13,081,390 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 31, 6:28 pm EDT | Raul Cardona TorresSVP, Quality | 13,112 | — | — | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:27 pm EDT | Eric SherbetGeneral Counsel and Secretary | 361,477 | $35.00 | $4,535,825 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 31, 6:27 pm EDT | Craig Eric SchneierEVP and Chief Talent Officer | 48,755 | $35.00 | $1,706,425 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:27 pm EDT | Rebecca Holland NewEVP, Enterprise Operations | 458,434 | $35.00 | $10,030,475 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:26 pm EDT | Francisco R. NegronPresident, Drug Product Svcs | 602,722 | $35.00 | $11,555,915 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:26 pm EDT | James C MullenChief Executive Officer, Director | 3,615,379 | $35.00 | $91,528,115 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:26 pm EDT | Michael J. LehmannEVP, Global Sales and Mktng | 576,492 | $35.00 | $13,081,390 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:25 pm EDT | Stuart GrantEVP and CFO | 763,088 | $35.00 | $19,831,105 | 0 | — | plan? |
| Aug 29, 2017 JUForm 4 → | Aug 31, 6:25 pm EDT | Harry R Gill IIISVP, Quality/Continuous Imprvt | 417,972 | $35.00 | $10,678,290 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 31, 6:24 pm EDT | Gilles CottierPresident, Pharma Dev Svcs | 70,141 | — | — | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:04 pm EDT | Stephan B. TandaDirector | 4,659 | $35.00 | $163,065 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:04 pm EDT | Gary P. PisanoDirector | 17,447 | $35.00 | $610,645 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:04 pm EDT | Jeffrey P McMullenDirector | 27,447 | $35.00 | $960,645 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:03 pm EDT | Paul S LevyDirector | 62,000 | $35.00 | $2,170,000 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:03 pm EDT | JLL Associates G.P. V (Patheon), Ltd. +310% Owner | 62,466,844 | $35.00 | $2,186,339,540 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:03 pm EDT | William B HayesDirector | 17,447 | $35.00 | $610,645 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:02 pm EDT | Hans Peter HaslerDirector | 16,864 | $35.00 | $590,240 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:02 pm EDT | Philip EykermanDirector | 28,000 | $35.00 | $980,000 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:02 pm EDT | Pamela DaleyDirector | 67,120 | $35.00 | $2,349,200 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 7:01 pm EDT | Charles I CogutDirector | 4,061 | $35.00 | $142,135 | 0 | — | plan? |
| Aug 29, 2017 UForm 4 → | Aug 30, 8:32 am EDT | Koninklijke DSM N.V.10% Owner | 48,697,292 | $35.00 | $1,704,405,220 | 0 | — | plan? |
| Jul 20, 2017 FForm 4 → | Jul 24, 12:06 pm EDT | Michel LagardePresident | 34,625 | $34.90 | $1,208,413 | 245,939 | — | plan? |
| Jul 20, 2017 FForm 4 → | Jul 24, 12:04 pm EDT | Craig Eric SchneierExecutive Vice President & CTO | 5,914 | $34.90 | $206,399 | 48,755 | — | plan? |
| Jul 20, 2017 FForm 4 → | Jul 24, 12:00 pm EDT | Raul Cardona TorresSVP, Quality | 786 | $34.90 | $27,431 | 13,112 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:27 pm EDT | Raul Cardona TorresSVP, Quality | 6,606 | — | — | 13,898 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:22 pm EDT | James C MullenCEO, Director | 93,432 | — | — | 1,000,290 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:20 pm EDT | Michel LagardePresident | 42,469 | — | — | 280,564 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:17 pm EDT | Francisco R. NegronPresident, Drug Product Svcs | 11,231 | — | — | 272,553 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:14 pm EDT | Rebecca Holland NewEVP, Enterprise Operations | 10,306 | — | — | 171,849 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:12 pm EDT | Eric SherbetGeneral Counsel and Secretary | 12,552 | — | — | 231,882 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:09 pm EDT | Harry R Gill IIISVP, Quality & Improvement | 7,078 | — | — | 112,878 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:00 pm EDT | Lukas UtigerPresident, Drug Substance | 12,420 | — | — | 204,192 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 2:56 pm EDT | Michael J. LehmannEVP, Sales & Marketing | 10,966 | — | — | 202,738 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 2:50 pm EDT | Dean Frederick WilsonChief Accounting Officer | 8,519 | — | — | 126,518 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 2:47 pm EDT | Gary P. PisanoDirector | 6,229 | — | — | 17,447 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 2:01 pm EDT | Jeffrey P McMullenDirector | 6,229 | — | — | 17,447 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 1:55 pm EDT | Hans Peter HaslerDirector | 7,126 | — | — | 16,864 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 1:38 pm EDT | William B HayesDirector | 6,229 | — | — | 17,447 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 1:35 pm EDT | Stephan B. TandaDirector | 4,659 | — | — | 4,659 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 1:24 pm EDT | Pamela DaleyDirector | 7,102 | — | — | 18,320 | — | plan? |
| Mar 23, 2017 AForm 4 → | Mar 27, 1:20 pm EDT | Charles I CogutDirector | 4,061 | — | — | 4,061 | — | plan? |
| Nov 1, 2016 FMForm 4 → | Nov 2, 3:58 pm EDT | Jeffrey P McMullenDirector | 12,592 | $25.61 | $17,594 | 11,218 | — | plan? |
| Nov 1, 2016 FMForm 4 → | Nov 2, 3:56 pm EDT | Gary P. PisanoDirector | 12,592 | $25.61 | $17,594 | 11,218 | — | plan? |
| Nov 1, 2016 FMForm 4 → | Nov 2, 3:55 pm EDT | Hans Peter HaslerDirector | 14,072 | $25.61 | $55,497 | 9,738 | — | plan? |
| Nov 1, 2016 FMForm 4 → | Nov 2, 3:51 pm EDT | William B HayesDirector | 12,592 | $25.61 | $17,594 | 11,218 | — | plan? |
| Nov 1, 2016 FMForm 4 → | Nov 2, 3:49 pm EDT | Pamela DaleyDirector | 12,592 | $25.61 | $17,594 | 11,218 | — | plan? |
| Sep 29, 2016 PForm 4 → | Oct 3, 8:11 pm EDT | Paul S LevyDirector | 10,000 | $29.55 | $295,500 | 62,000 | +19.2% | plan? |
| Sep 26, 2016 PForm 4 → | Sep 28, 7:16 pm EDT | Paul S LevyDirector | 15,000 | $29.64 | $444,550 | 52,000 | +40.5% | plan? |
| Sep 12, 2016 PForm 4 → | Sep 14, 4:10 pm EDT | Paul S LevyDirector | 37,000 | $28.01 | $1,036,370 | 37,000 | — | plan? |
| Jul 26, 2016 PForm 4 → | Jul 28, 5:51 pm EDT | JLL Associates G.P. V (Patheon), Ltd. +310% Owner | 815,730 | $19.85 | $16,188,162 | 40,287 | — | plan? |
| Jul 26, 2016 PForm 4 → | Jul 28, 5:51 pm EDT | Jeffrey P McMullenDirector | 10,000 | $19.85 | $198,450 | 21,905 | +84.0% | plan? |
| Jul 26, 2016 PForm 4 → | Jul 28, 5:51 pm EDT | Pamela DaleyDirector | 48,800 | $19.85 | $968,436 | 60,705 | +410% | plan? |
| Jul 26, 2016 SForm 4 → | Jul 28, 4:05 pm EDT | Koninklijke DSM N.V.10% Owner | 4,761,905 | $19.85 | $94,500,005 | 48,697,292 | −8.91% | plan? |
| Jul 21, 2016 PForm 4 → | Jul 25, 7:47 pm EDT | Philip EykermanDirector | 28,000 | $25.00 | $700,000 | 28,000 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:25 pm EDT | Dean Frederick WilsonChief Accounting Officer | 117,999 | — | — | 117,999 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:24 pm EDT | Lukas UtigerPresident, Drug Substance Svcs | 191,772 | — | — | 191,772 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:24 pm EDT | Eric SherbetGeneral Counsel and Secretary | 219,330 | — | — | 219,330 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:24 pm EDT | Gary P. PisanoDirector | 11,905 | — | — | 11,905 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:23 pm EDT | Rebecca Holland NewEVP, Enterprise Operations | 161,543 | — | — | 161,543 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:23 pm EDT | Francisco R. NegronPresident, Drug Product Svcs | 261,322 | — | — | 261,322 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:23 pm EDT | James C MullenChief Executive Officer, Director | 906,858 | — | — | 906,858 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:23 pm EDT | Jeffrey P McMullenDirector | 11,905 | — | — | 11,905 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:22 pm EDT | Michael LyttonEVP, Corp Development & Strtgy | 227,201 | — | — | 227,201 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:22 pm EDT | Michael J. LehmannEVP, Global Sales and Mktng | 191,772 | — | — | 191,772 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:22 pm EDT | Michel LagardePresident | 238,095 | — | — | 238,095 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:21 pm EDT | William B HayesDirector | 11,905 | — | — | 11,905 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:21 pm EDT | Hans Peter HaslerDirector | 11,905 | — | — | 11,905 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:21 pm EDT | Stuart GrantEVP and CFO | 196,485 | — | — | 196,485 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:20 pm EDT | Harry R Gill IIISVP, Quality/Continuous Imprvt | 105,800 | — | — | 105,800 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:20 pm EDT | Pamela DaleyDirector | 11,905 | — | — | 11,905 | — | plan? |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:20 pm EDT | Gilles CottierPresident, Pharma Dev Svcs | 70,141 | — | — | 70,141 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 29, 2017 DForm 4 → | Aug 31, 6:30 pm EDT | Michel LagardePresident | 110,402 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:28 pm EDT | Lukas UtigerPresident, Drug Substance Svcs | 32,287 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:28 pm EDT | Raul Cardona TorresSVP, Quality | 38,960 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:27 pm EDT | Eric SherbetGeneral Counsel and Secretary | 32,630 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:27 pm EDT | Craig Eric SchneierEVP and Chief Talent Officer | 96,455 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:27 pm EDT | Rebecca Holland NewEVP, Enterprise Operations | 26,791 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:26 pm EDT | Francisco R. NegronPresident, Drug Product Svcs | 29,195 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:26 pm EDT | James C MullenChief Executive Officer, Director | 242,885 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:26 pm EDT | Michael J. LehmannEVP, Global Sales and Mktng | 28,508 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:25 pm EDT | Harry R Gill IIISVP, Quality/Continuous Imprvt | 18,400 | — | — | 0 | — | |
| Aug 29, 2017 DForm 4 → | Aug 31, 6:24 pm EDT | Gilles CottierPresident, Pharma Dev Svcs | 123,754 | — | — | 0 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:27 pm EDT | Raul Cardona TorresSVP, Quality | 17,174 | — | — | 17,174 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:22 pm EDT | James C MullenCEO, Director | 242,885 | — | — | 242,885 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:20 pm EDT | Michel LagardePresident | 110,402 | — | — | 110,402 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:17 pm EDT | Francisco R. NegronPresident, Drug Product Svcs | 29,195 | — | — | 29,195 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:14 pm EDT | Rebecca Holland NewEVP, Enterprise Operations | 26,791 | — | — | 26,791 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:12 pm EDT | Eric SherbetGeneral Counsel and Secretary | 32,630 | — | — | 32,630 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:09 pm EDT | Harry R Gill IIISVP, Quality & Improvement | 18,400 | — | — | 18,400 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 3:00 pm EDT | Lukas UtigerPresident, Drug Substance | 32,287 | — | — | 32,287 | — | |
| Mar 23, 2017 AForm 4 → | Mar 27, 2:56 pm EDT | Michael J. LehmannEVP, Sales & Marketing | 28,508 | — | — | 28,508 | — | |
| Jul 20, 2016 AForm 4 → | Jul 22, 5:20 pm EDT | Gilles CottierPresident, Pharma Dev Svcs | 123,754 | — | — | 123,754 | — |